Ji-Xiang Zhang

Dr. Ji-Xiang Zhang


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2007 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LLLiang-Ming Liu
Liang-Ming Liu
JZJi-Xiang Zhang
Ji-Xiang Zhang
JLJie Luo
Jie Luo
HGHong-Xing Guo
Hong-Xing Guo
HDHuan Deng
Huan Deng
SSSui-Lin Sun
Sui-Lin Sun

26 May 2010 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
WGWu-Hua Guo
Wu-Hua Guo
LYLi-Hua Yuan
Li-Hua Yuan
ZXZhi-Hua Xiao
Zhi-Hua Xiao
DLDan Liu
Dan Liu
JZJi-Xiang Zhang
Ji-Xiang Zhang

1 January 2015 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
JZJi-Xiang Zhang
Ji-Xiang Zhang
JZJian-Feng Zheng
Jian-Feng Zheng
JLJuan Lu
Juan Lu
XWXiao-Zhong Wang
Xiao-Zhong Wang
WGWuhua Guo
Wuhua Guo
BACKGROUND:Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC). To better understand this effect, we comparatively profiled the metabolite composition of HepG2 cells treated wit...

13 January 2010 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
LLL.‐M. Liu
L.‐M. Liu
JZJi-Xiang Zhang
Ji-Xiang Zhang
XWX.‐P. Wang
X.‐P. Wang
HGH.‐X. Guo
H.‐X. Guo
HDH. Deng
H. Deng
JLJ. Luo
J. Luo

25 January 2011 in Medical Oncology
Verified
Journal Article
Closed access
HWHong-Yun Wang
Hong-Yun Wang
GXGao-Fei Xiong
Gao-Fei Xiong
JZJi-Xiang Zhang
Ji-Xiang Zhang
HXHong Xu
Hong Xu
WGWu-Hua Guo
Wu-Hua Guo
XXXiang-Yang Xiong
Xiang-Yang Xiong

1 January 2015 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
JZJi-Xiang Zhang
Ji-Xiang Zhang
JZJian-Feng Zheng
Jian-Feng Zheng
LLLin-Lin Li
Lin-Lin Li
JLJuan Lu
Juan Lu
KYKun Yan
Kun Yan
WGWuhua Guo
Wuhua Guo
Recent clinical studies have linked polymorphisms in the xeroderma pigmentosum group D (XPD) gene, a key repair gene involved in nucleotide excision repair, to increased risk of hepatocellular carcinoma (HCC). However, the cellular effects of XPD expression in cultured HCC cells remain largely uncharacterized. Therefore, the aim of this study was to characterize the in vitro cellular effects of XPD expression on the HCC cell line HepG2. HepG2 cells were transfected as follows to create four experimental groups: pEGFP-N2/XPD plasmid (XPD) group, EGFP-N2 plasmid (N2) control group, lipofectamine™ 2000 (lipid) control group, and non-transfected (CON) control group. An MTT cell proliferation assay, Annexin V-APC apoptosis assay, colony formation assay, scratch wound migration assay, Transwell migration assay, and Western blotting of the autophagic proteins LC3 and p62 were conducted. XPD expression significantly inhibited HepG2 cell proliferation (p<0.05), significantly promoted HepG2 cell apoptosis (p<0.05), significantly inhibited HepG2 colony formation (p<0.05), significantly decreased HepG2 cells' migratory ability (p<0.05), and significantly lowered HepG2 cells' invasive capacity (p<0.05). Western blotting showed that XPD expression significantly increased LC3 expression (p<0.05) and significantly reduced p62 expression (p<0.05). XPD expression serves as a tumor suppressor and dysregulates autophagic protein degradation in HepG2 cells in vitro. Further in vivo pre-clinical studies and clinical trials are needed to validate XPD's potential as a tumor-suppressive gene therapy.